Jun 25, 2026
The US FTC is challenging a court ruling involving Johnson & Johnson's patent acquisition for Stelara, arguing it could weaken antitrust enforcement in pharma. Separately, Turkey's Court of Cassation ruled that patent holders who file infringement actions and send warning letters to third parties are exercising lawful patent rights, dismissing an unfair competition claim by a generic company.
Jun 23, 2026
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
Jun 09, 2026
The FDA is receiving extensive industry feedback on three regulatory initiatives: draft guidance for using new approach methodologies to reduce animal testing, the Commissioner's National Priority Voucher pilot program, and a proposed rule to update the National Drug Code format. Stakeholders are urging revisions to the NAMs guidance, improvements to the CNPV program, and timely finalization of the NDC rule to avoid disruptions.
May 29, 2026
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
May 23, 2026
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 09, 2026
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
May 05, 2026
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
May 02, 2026
A Pennsylvania jury ordered Johnson & Johnson to pay $250,000 to the family of Gayle Emerson in a talc baby powder ovarian cancer case. The verdict comes amid more than 90,000 talc lawsuits and ongoing fights over expert testimony.
Apr 19, 2026
Healthcare stocks were described as a defensive sector facing 2026 reimbursement headwinds, while capex rankings showed HCA Healthcare, Johnson & Johnson and Merck at the top. The sources also highlighted how capex differs across providers, device makers and drug developers.
Apr 15, 2026
Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.
Apr 11, 2026
Johnson & Johnson said revenue could reach about $100.5 billion at the midpoint in 2026 after 2024 net sales rose 6% to $94.2 billion. The company faces talc litigation, Stelara patent losses and U.S. drug price negotiations.
Apr 11, 2026
Johnson & Johnson shares hit a 52-week high after the company reported 2025 revenue of $94.19 billion and forecast 2026 revenue above $100 billion. The company also filed a shelf registration and said Innovative Medicine growth offset pressure from Stelara.
Apr 08, 2026
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
Apr 08, 2026
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
Apr 07, 2026
Johnson & Johnson is scheduled to release Q1 2026 earnings on April 14, with analysts forecasting $2.68 per share and $23.6 billion in revenue. The healthcare giant recently reported strong Q4 2025 results that beat estimates. The company maintains a 62-year dividend increase history with a 64% payout ratio.
Apr 06, 2026
Blackstone closed its sixth dedicated life sciences fund at a $6.3 billion hard cap, the largest private fund raised for the sector. The vehicle is nearly 40% larger than its 2020 predecessor and targets late-stage drug assets.
Apr 04, 2026
Large-cap healthcare stocks such as Johnson & Johnson and CVS Health are viewed as defensive in a slowdown, with beta values of 0.33 and 0.46. Investors can also pursue higher-risk healthcare companies such as Grail and Viking Therapeutics, whose performance depends more on clinical and product milestones.
Apr 03, 2026
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Apr 01, 2026
Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
